LLY

1,102.5

+0.95%↑

JNJ

207.31

+0.22%↑

ABBV

227.86

-1.85%↓

UNH

330.44

+1.66%↑

AZN

93.65

+0.84%↑

LLY

1,102.5

+0.95%↑

JNJ

207.31

+0.22%↑

ABBV

227.86

-1.85%↓

UNH

330.44

+1.66%↑

AZN

93.65

+0.84%↑

LLY

1,102.5

+0.95%↑

JNJ

207.31

+0.22%↑

ABBV

227.86

-1.85%↓

UNH

330.44

+1.66%↑

AZN

93.65

+0.84%↑

LLY

1,102.5

+0.95%↑

JNJ

207.31

+0.22%↑

ABBV

227.86

-1.85%↓

UNH

330.44

+1.66%↑

AZN

93.65

+0.84%↑

LLY

1,102.5

+0.95%↑

JNJ

207.31

+0.22%↑

ABBV

227.86

-1.85%↓

UNH

330.44

+1.66%↑

AZN

93.65

+0.84%↑

Search

Denali Therapeutics Inc

Abrir

SetorSaúde

19.18 -1.08

Visão Geral

Variação de preço das ações

24h

Atual

Mín

18.65

Máximo

19.54

Indicadores-chave

By Trading Economics

Rendimento

-2.8M

-127M

Funcionários

517

EBITDA

-2M

-123M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+64.5% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

530M

2.8B

Abertura anterior

20.26

Fecho anterior

19.18

Sentimento de Notícias

By Acuity

67%

33%

337 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Denali Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de nov. de 2025, 16:56 UTC

Ganhos
Grandes Movimentos do Mercado

Alimentation Couche-Tard Shares Rise as 2Q Same-Store Sales Support Profit Growth

25 de nov. de 2025, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 de nov. de 2025, 23:47 UTC

Conversa de Mercado

Nikkei May Rise After Stock Gains on Wall Street -- Market Talk

25 de nov. de 2025, 22:39 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

25 de nov. de 2025, 22:39 UTC

Conversa de Mercado

Vault Accelerates Exposure to Spot Gold Prices by Six Months -- Market Talk

25 de nov. de 2025, 21:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

25 de nov. de 2025, 21:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

25 de nov. de 2025, 21:38 UTC

Ganhos

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25 de nov. de 2025, 21:31 UTC

Conversa de Mercado

F&P Healthcare's Share Price Jumps on Profit Guidance Upgrade -- Market Talk

25 de nov. de 2025, 21:27 UTC

Ganhos

These Stocks Moved the Most Today: Nvidia, AMD, Alphabet, Abercrombie, Kohl's, Novo Nordisk, Symbotic, and More -- Barrons.com

25 de nov. de 2025, 21:20 UTC

Ganhos

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25 de nov. de 2025, 21:18 UTC

Ganhos

NIO Stock Drops as EV Maker Posts Narrower Loss -- Barrons.com

25 de nov. de 2025, 21:15 UTC

Ganhos

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25 de nov. de 2025, 20:16 UTC

Conversa de Mercado

U.S. Natural Gas Falls as December Contract Expires -- Market Talk

25 de nov. de 2025, 18:42 UTC

Conversa de Mercado

USDA Backs Mexican Retail Expo to Raise Agricultural Exports -- Market Talk

25 de nov. de 2025, 18:25 UTC

Aquisições, Fusões, Aquisições de Empresas

S&P Global Completes $1.8 Billion Acquisition Of With Intelligence, Strengthening Its Position As A Leader In Private Markets Data & Analytics >SPGI

25 de nov. de 2025, 17:30 UTC

Conversa de Mercado

Mexico Posts Record Foreign Direct Investment for Jan-Sep -- Market Talk

25 de nov. de 2025, 17:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

25 de nov. de 2025, 17:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

25 de nov. de 2025, 16:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Eni: Financial Details Weren't Disclosed

25 de nov. de 2025, 16:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Eni: Block OFF-5 Covers an Area of About 17,000 Km Sq. in Water Depths

25 de nov. de 2025, 16:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Eni: Agreement to Become Effective After Approval of Uruguayan Authorities

25 de nov. de 2025, 16:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Eni: Acquisition Is for a 50% Share, Operatorship in Exploration Block OFF-5

25 de nov. de 2025, 16:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Eni Acquires From YPF Shares in the Exploration Block OFF-5 Offshore Uruguay

25 de nov. de 2025, 16:23 UTC

Ganhos

This Robotics Stock Soars 40% on Earnings. Here's Why. -- Barrons.com

25 de nov. de 2025, 16:12 UTC

Conversa de Mercado

Euro Expected to Rise to $1.25 in 2026: Deutsche Bank -- Market Talk

25 de nov. de 2025, 16:11 UTC

Conversa de Mercado

Dollar Could Take One Final Leg Lower in Early 2026 -- Market Talk

25 de nov. de 2025, 16:10 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 de nov. de 2025, 16:10 UTC

Conversa de Mercado

Sterling Could Briefly Rise After Budget -- Market Talk

25 de nov. de 2025, 16:10 UTC

Conversa de Mercado

Oil Extends Losses on Ukraine-Russia Peace Deal Hopes -- Market Talk

Comparação entre Pares

Variação de preço

Denali Therapeutics Inc Previsão

Preço-alvo

By TipRanks

64.5% parte superior

Previsão para 12 meses

Média 31.14 USD  64.5%

Máximo 37 USD

Mínimo 26 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

10 ratings

10

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

13.355 / 16.44Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Strong Bearish Evidence

Sentimento

By Acuity

337 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat